Search

Author/Creator Ning, Xiaoping

1. Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials. Issue 6 (12th April 2019)

Authors:
Silberstein, Stephen D.; McAllister, Peter; Ning, Xiaoping; Faulhaber, Nicola; Lang, Nicole; Yeung, Paul; Schiemann, Jimmy; Aycardi, Ernesto; Cohen, Joshua M.; Janka, Lindsay; Yang, Ronghua
Journal:
Headache
Issue:
Volume 59:Issue 6(2019)
Page Start:
880
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach. (September 2021)

Authors:
Cohen-Barak, Orit; Radivojevic, Andrijana; Jones, Aksana; Fiedler-Kelly, Jill; Gillespie, Michael; Brennan, Michael; Gutman, Dikla; Rasamoelisolo, Michele; Hallak, Hussein; Loupe, Pippa; Kessler, Yoel; Ning, Xiaoping; Levi, Micha; Ahn, Andrew H; Rabinovich-Guilatt, Laura
Journal:
Cephalalgia
Issue:
Volume 41:Number 10(2021)
Page Start:
1065
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. 056  Efficacy of fremanezumab in chronic migraine patients with inadequate response to ≥3 preventive medication classes. Issue 6 (27th May 2022)

Authors:
Lambru, Giorgio; Dhiraj, Dalbir; Ning, Xiaoping; Campos, Verena Ramirez; Barash, Steve; Sherwin, Eoin; Cohen, Joshua
Journal:
Journal of neurology, neurosurgery and psychiatry
Issue:
Volume 93:Issue 6(2022)
Page Start:
A118
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies. (July 2022)

Authors:
Diener, Hans Christoph; McAllister, Peter; Jürgens, Tim P; Kessler, Yoel; Ning, Xiaoping; Cohen, Joshua M; Campos, Verena Ramirez; Barash, Steve; Silberstein, Stephen D
Journal:
Cephalalgia
Issue:
Volume 42:Number 8(2022)
Page Start:
769
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Efficacy and quality‐of‐life improvements with fremanezumab treatment in patients with difficult‐to‐treat migraine with associated neurological dysfunction. (29th March 2022)

Authors:
Lampl, Christian; Rapoport, Alan M.; Cohen, Joshua M.; Barash, Steve; Ramirez Campos, Verena; Seminerio, Michael J.; Ning, Xiaoping; Silberstein, Stephen D.
Journal:
European journal of neurology
Issue:
Volume 29:Number 7(2022)
Page Start:
2129
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients. Issue 7 (29th July 2021)

Authors:
Sakai, Fumihiko; Suzuki, Norihiro; Kim, Byung‐Kun; Tatsuoka, Yoshihisa; Imai, Noboru; Ning, Xiaoping; Ishida, Miki; Nagano, Kaori; Iba, Katsuhiro; Kondo, Hiroyuki; Koga, Nobuyuki
Journal:
Headache
Issue:
Volume 61:Issue 7(2021)
Page Start:
1102
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗